trending Market Intelligence /marketintelligence/en/news-insights/trending/E9MVa6ztndMWdOIP58bkYA2 content esgSubNav
In This List

Mirati Therapeutics starts $75M underwritten public offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Mirati Therapeutics starts $75M underwritten public offering

Mirati Therapeutics Inc. started a $75 million underwritten public offering of its common shares.

The San Diego-based biotechnology company will give underwriters an option to buy up to an additional $11.3 million in shares.

J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Cowen and Co. LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC are offering's joint book-running managers.

Mirati Therapeutics develops drugs that target genetic changes in cancer cells which cause tumors to grow and spread.